Literature DB >> 10464010

Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.

P Camps1, R El Achab, D M Görbig, J Morral, D Muñoz-Torrero, A Badia, J Eladi Baños, N M Vivas, X Barril, M Orozco, F J Luque.   

Abstract

Eleven new 12-amino-6,7,10,11-tetrahydro-7, 11-methanocycloocta[b]quinoline derivatives [tacrine (THA)-huperzine A hybrids, rac-21-31] have been synthesized as racemic mixtures and tested as acetylcholinesterase (AChE) inhibitors. For derivatives unsubstituted at the benzene ring, the highest activity was obtained for the 9-ethyl derivative rac-20, previously prepared by our group. More bulky substituents at position 9 led to less active compounds, although some of them [9-isopropyl (rac-22), 9-allyl (rac-23), and 9-phenyl (rac-26)] show activities similar to that of THA. Substitution at position 1 or 3 with methyl or fluorine atoms always led to more active compounds. Among them, the highest activity was observed for the 3-fluoro-9-methyl derivative rac-28 [about 15-fold more active than THA and about 9-fold more active than (-)-huperzine A]. The activity of some THA-huperzine A hybrids (rac-19, rac-20, rac-28, and rac-30), which were separated into their enantiomers by chiral medium-pressure liquid chromatography (chiral MPLC), using microcrystalline cellulose triacetate as the chiral stationary phase, showed the eutomer to be always the levorotatory enantiomer, their activity being roughly double that of the corresponding racemic mixture, the distomer being much less active. Also, the activity of some of these compounds inhibiting butyrylcholinesterase (BChE) was tested. Most of them [rac-27-31, (-)-28, and (-)-30], which are more active than (-)-huperzine A as AChE inhibitors, turned out to be quite selective for AChE, although not so selective as (-)-huperzine A. Most of the tested compounds 19-31 proved to be much more active than THA in reversing the neuromuscular blockade induced by d-tubocurarine. Molecular modeling of the interaction of these compounds with AChE from Torpedo californica showed them to interact as truly THA-huperzine A hybrids: the 4-aminoquinoline subunit of (-)-19 occupies the same position of the corresponding subunit in THA, while its bicyclo[3.3.1]nonadiene substructure roughly occupies the same position of the corresponding substructure in (-)-huperzine A, in agreement with the absolute configurations of (-)-19 and (-)-huperzine A.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464010     DOI: 10.1021/jm980620z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Effect of acetylcholinesterase inhibitors on AChE-induced PrP106-126 aggregation.

Authors:  M V Clos; M Pera; M Ratia; S Román; P Camps; D Muñoz-Torrero; L Colombo; M Salmona; A Badia
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  Huprines as a new family of dual acting trypanocidal-antiplasmodial agents.

Authors:  Julien Defaux; Marta Sala; Xavier Formosa; Carles Galdeano; Martin C Taylor; Waleed A A Alobaid; John M Kelly; Colin W Wright; Pelayo Camps; Diego Muñoz-Torrero
Journal:  Bioorg Med Chem       Date:  2011-01-21       Impact factor: 3.641

Review 3.  Hybrids: a new paradigm to treat Alzheimer's disease.

Authors:  Manjinder Singh; Maninder Kaur; Navriti Chadha; Om Silakari
Journal:  Mol Divers       Date:  2015-09-02       Impact factor: 2.943

4.  Binding free energy calculations to rationalize the interactions of huprines with acetylcholinesterase.

Authors:  Érica C M Nascimento; Mónica Oliva; Juan Andrés
Journal:  J Comput Aided Mol Des       Date:  2018-03-26       Impact factor: 3.686

5.  Identification of selective inhibitors of acetylcholinesterase from a combinatorial library of 2,5-piperazinediones.

Authors:  T Carbonell; I Masip; F Sánchez-Baeza; M Delgado; E Araya; O Llorens; F Corcho; J J Pérez; E Pérez-Payá; A Messeguer
Journal:  Mol Divers       Date:  2000       Impact factor: 2.943

6.  Design, synthesis and docking study of novel coumarin ligands as potential selective acetylcholinesterase inhibitors.

Authors:  Fatih Sonmez; Belma Zengin Kurt; Isil Gazioglu; Livia Basile; Aydan Dag; Valentina Cappello; Tiziana Ginex; Mustafa Kucukislamoglu; Salvatore Guccione
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

7.  Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis.

Authors:  Carles Galdeano; Nicolas Coquelle; Monika Cieslikiewicz-Bouet; Manuela Bartolini; Belén Pérez; M Victòria Clos; Israel Silman; Ludovic Jean; Jacques-Philippe Colletier; Pierre-Yves Renard; Diego Muñoz-Torrero
Journal:  Molecules       Date:  2018-03-11       Impact factor: 4.411

8.  Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors.

Authors:  Tania Castaño; Huanchen Wang; Nuria E Campillo; Sara Ballester; Coral González-García; Javier Hernández; Concepción Pérez; Jimena Cuenca; Ana Pérez-Castillo; Ana Martínez; Oscar Huertas; José Luis Gelpí; F Javier Luque; Hengming Ke; Carmen Gil
Journal:  ChemMedChem       Date:  2009-05       Impact factor: 3.466

9.  Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines.

Authors:  María D Duque; Pelayo Camps; Lenuta Profire; Silvia Montaner; Santiago Vázquez; Francesc X Sureda; Jordi Mallol; Marta López-Querol; Lieve Naesens; Erik De Clercq; S Radhika Prathalingam; John M Kelly
Journal:  Bioorg Med Chem       Date:  2009-02-13       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.